Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlumisALMS +3.45%12 EV-to-EBITDA is -6.95 as of Jul. 15, 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 398 Biotechnology companies, Alumis ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alumis's enterprise value is $3,107.99 Mil.
Alumis's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-447.16 Mil. Therefore, Alumis's EV-to-EBITDA for today is -6.95.
The historical rank and industry rank for Alumis's EV-to-EBITDA or its related term are showing as below:
ALMS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.95 Med: -1.03 Max: 0.44
Current: -6.95
During the past 4 years, the highest EV-to-EBITDA of Alumis was 0.44. The lowest was -6.95. And the median was -1.03.
ALMS's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.62
vs ALMS: -6.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-15), Alumis's stock price is $28.20.
Alumis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.960. Therefore, Alumis's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Alumis (NAS:ALMS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alumis's share price for today is $28.20.
Alumis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alumis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alumis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alumis EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alumis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alumis's EV-to-EBITDA falls into.
Alumis's current Enterprise Value is $3,107.99 Mil.
Alumis's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-447.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alumis (ALMS) has a EV-to-EBITDA of -6.95 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alumis. According to the industry distribution chart, Alumis ranks #999999 out of 398 companies in the Biotechnology industry.
Is Alumis' EV-to-EBITDA too high?
Alumis' current EV-to-EBITDA is -6.95. Based on the distribution chart, Alumis ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' EV-to-EBITDA compare to ARQT and QURE?
According to the Biotechnology industry distribution chart, Alumis ranks #999999 out of 398 companies for EV-to-EBITDA. This places Alumis in the lower half of its industry. The industry median EV-to-EBITDA is 12.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.62, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alumis. For the Biotechnology industry, the median EV-to-EBITDA is 12.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alumis's current EV-to-EBITDA is -6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current EV-to-EBITDA of -6.95. The current EV-to-EBITDA is -6.95. Alumis' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alumis (ALMS), the current EV-to-EBITDA is -6.95 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score
Get the complete analysis for ALMS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMS has been successfully added to your 
